/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.
WIRE SERVICES/
WINNIPEG, Dec. 7, 2017 /CNW/ - DELTA 9 CANNABIS INC. (TSXV:
NINE) ("Delta 9" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters
led by Canaccord Genuity Corp. (the "Underwriters") pursuant to which the Underwriters have agreed to purchase, on a bought deal
basis pursuant to the filing of a short form prospectus, an aggregate of 7,410,000 units (the "Units") at a price of $2.70 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of $20,007,000 (the "Offering").
Each Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (each whole
Common Share purchase warrant, a "Warrant"). Each Warrant will be exercisable to acquire one Common Share (a "Warrant Share") for
a period of 30 months following the closing of the Offering (the "Closing") at an exercise price of $3.25 per Warrant Share.
The Company has granted the Underwriter an option (the "Over-Allotment Option"), to purchase up to an additional 1,111,500
Units at a price of C$2.70 per Unit, exercisable at any time, for a period of 30 days after and
including the Closing Date. The Over-Allotment Option is exercisable to acquire Units, Common Shares and/or Warrants (or any
combination thereof) at the discretion of the Underwriter.
The net proceeds of the Offering will be used to for expansion capital expenditures and general corporate purposes.
The Units will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec. The Offering is expected to close on December 28, 2017 and is subject to certain conditions including, but not limited to, the receipt of all
necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange and the applicable
securities regulatory authorities.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as
amended, and may not be offered or sold in the United States or to, or for the account or
benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release
will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any
state in which such offer, solicitation or sale would be unlawful.
About Delta 9 Cannabis Inc.
Delta 9's wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the
ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada.
Delta 9's shares trade on the TSX Venture Exchange under the symbol "NINE".
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the
Company's future business plans and other matters. Forward-looking statements consist of statements that are not purely
historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking
statements in this news release include statements relating to the closing of the Offering and the use of proceeds of the
Offering. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to
differ materially from those contained in the statements, including that Delta 9's currently contemplated expansion and
development plans may cease or otherwise change, Delta 9's production of cannabis may be lower than expected, Delta 9 may not
obtain the required approvals from Health Canada, demand for Delta 9's products may be lower than anticipated, Delta 9's cost to
produce its grow pods may be higher than expected and all other risk factors set forth in the filing statement of Delta 9 dated
October 25, 2017 which has been filed on SEDAR. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them.
Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release
and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these
cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or
obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or
otherwise, except as required by applicable securities laws.
SOURCE Delta 9 Cannabis Inc.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/December2017/07/c8410.html